In our prospective study, PIMS could stratify anti-TNF refractory (primary or secondary nonresponse) IBD patients in regard to vedolizumab clinical response at week 14 with high specificity and good sensitivity (PPV 89% and NPV 82%). Here, TNF is linked to inflammatory bowel disease.